Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

Journal of Ovarian Research

Carita Lannér³  Stephanie Cull¹  Katherine L McCallum⁴  Amadeo M Parissenti⁴  Baoqing Guo¹  Rashmi Narendrula²  Stephen R Armstrong² 

[1] Sudbury Regional Cancer Center, Cancer Research Laboratory, Sudbury, ON, P3E5JI, Canada;Dept. of Biology, Laurentian University, Sudbury, ON, P3E2C6, Canada;Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON, P3E2C6, Canada;Division of Medical Sciences, Northern Ontario School of Medicine, Laurentian University campus, Sudbury, ON, P3E2C6, Canada

关键词: A2780 cell line;    Microarray analysis;    Docetaxel;    Carboplatin;    Multidrug resistance;    Ovarian cancer;   

Others  :  814712
DOI  :  10.1186/1757-2215-5-40

 received in 2012-07-30, accepted in 2012-10-22,  发布年份 2012

【 摘 要 】

Background

Current protocols for the treatment of ovarian cancer include combination chemotherapy with a platinating agent and a taxane. However, many patients experience relapse of their cancer and the development of drug resistance is not uncommon, making successful second line therapy difficult to achieve. The objective of this study was to develop and characterize a cell line resistant to both carboplatin and docetaxel (dual drug resistant ovarian cell line) and to compare this cell line to cells resistant to either carboplatin or docetaxel.

Methods

The A2780 epithelial endometrioid ovarian cancer cell line was used to select for isogenic carboplatin, docetaxel and dual drug resistant cell lines. A selection method of gradually increasing drug doses was implemented to avoid clonal selection. Resistance was confirmed using a clonogenic assay. Changes in gene expression associated with the development of drug resistance were determined by microarray analysis. Changes in the expression of selected genes were validated by Quantitative Real-Time Polymerase Chain Reaction (QPCR) and immunoblotting.

Results

Three isogenic cell lines were developed and resistance to each drug or the combination of drugs was confirmed. Development of resistance was accompanied by a reduced growth rate. The microarray and QPCR analyses showed that unique changes in gene expression occurred in the dual drug resistant cell line and that genes known to be involved in resistance could be identified in all cell lines.

Conclusions

Ovarian tumor cells can acquire resistance to both carboplatin and docetaxel when selected in the presence of both agents. Distinct changes in gene expression occur in the dual resistant cell line indicating that dual resistance is not a simple combination of the changes observed in cell lines exhibiting single agent resistance.

【 授权许可】

   
2012 Armstrong et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 9.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer Statistics, 2010. CA Cancer J Clin 2010, 60(5):277-286.
• [2]Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM: Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 2007, 109(4):692-702.
• [3]Markman M: Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Trends Pharmacol Sci 2008, 29(10):515-519.
• [4]Markman M: Pharmaceutical management of ovarian cancer: current status. Drugs 2008, 68(6):771-789.
• [5]du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005, 8(16 Suppl):viii7-viii12.
• [6]Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J: Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer. Acta Obstet Gynecol Scand 2009, 88(4):463-467.
• [7]Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM: Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27(9):1419-1425.
• [8]Stordal B, Pavlakis N, Davey R: A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 2007, 33(8):688-703.
• [9]Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J: Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 2004, 93(3):699-701.
• [10]Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB: Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 2006, 58(3):384-395.
• [11]Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33(1):9-23.
• [12]Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW: Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 2005, 92(6):1149-1158.
• [13]Peters D, Freund J, Ochs RL: Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Mol Cancer Ther 2005, 4(10):1605-1616.
• [14]Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G: ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008, 14(17):5594-5601.
• [15]Balat O, Kudelka AP, Edwards CL, Verschraegen CF, Kavanagh JJ: Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature. Eur J Gynaecol Oncol 1997, 18(5):341-342.
• [16]Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA: A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol 2004, 95(3):624-631.
• [17]Kavallaris M: Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010, 10:194-204.
• [18]Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K: Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 2007, 173(1):1-9.
• [19]Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM: cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 2006, 96(1):17-39.
• [20]Lu M, Xiao L, Li Z, Hu J: The Relationship between p38MAPK and Apoptosis during Paclitaxel Resistance of Ovarian Cancer Cells. J Huazhong University of Science and Technology 2007, 27(6):725-728.
• [21]Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G: Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005, 11(1):298-305.
• [22]Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C: Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 2012, 38(7):890-903.
• [23]Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005, 4(12):2001-2007.
• [24]Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 2002, 59(8):1406-1412.
• [25]DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH: Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol Oncol 2008, 108(2):355-360.
• [26]Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003, 88(2):130-135.
• [27]Rose PG, Smrekar M: Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Gynecol Oncol 2003, 91(2):423-425.
• [28]Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB: Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004, 96(22):1682-1691.
• [29]Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004, 10(22):7439-7449.
• [30]Verborg WA, Campbell LR, Highley MS, Rankin EM: Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer. Int J Gynecol Cancer 2008, 18(2):228-234.
• [31]Ozols RF: Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 2003, 21(13):2451-2453.
• [32]Markman M: Second-line therapy for ovarian cancer. Clin Adv Hematol Oncol 2008, 6(6):421-422.
• [33]Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J: Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Gynecol Oncol 2004, 95(1):109-113.
• [34]Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS: Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Gynecol Oncol 2004, 95(3):506-512.
• [35]Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26(1):76-82.
• [36]Jurado JM, Sanchez A, Pajares B, Perez E, Alonso L, Alba E: Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Clin Transl Oncol 2008, 10(9):583-586.
• [37]Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA: Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer 2008, 44(15):2169-2177.
• [38]Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003, 21(17):3194-3200.
• [39]Montella L, Addeo R, Guarrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M, Del Prete S: Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. Eur J Cancer Care (Engl) 2010, 19(2):200-204.
• [40]Tinker AV, Gebski V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, Goldrick A, Rischin D: Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel–ANZGOG 02–01. Gynecol Oncol 2007, 104(3):647-653.
• [41]Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM: Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 2004, 85(1):31-51.
• [42]Guo B, Hembruff SL, Villeneuve DJ, Kirwan AF, Parissenti AM: Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization. Breast Cancer Res Treat 2003, 82(2):125-141.
• [43]Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS: Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol 2005, 97(1):110-117.
• [44]Stordal B, Davey R: A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 2009, 9(3):354-365.
• [45]Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, Cull S, Maclean DA, Parissenti AM: Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet Genomics 2009, 19(6):477-488.
• [46]Chen T, Li M, Zhang R, Wang H: Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 2009, 13(7):1358-1370.
• [47]Grosse PY, Bressolle F, Pinguet F: In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin. Eur J Cancer 1998, 34(1):168-174.
• [48]Moss EL, Mourtada-Maarabouni M, Pickard MR, Redman CW, Williams GT: FAU regulates carboplatin resistance in ovarian cancer. Genes Chromosomes Cancer 2010, 49(1):70-77.
• [49]Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M: Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther 2006, 5(8):2086-2095.
• [50]Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J: The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Int J Cancer 2009, 124(4):806-815.
• [51]Tsuruo T, Hamilton TC, Louie KG, Behrens BC, Young RC, Ozols RF: Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. Jpn J Cancer Res 1986, 77(9):941-945.
• [52]Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF: Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987, 47(2):414-418.
• [53]Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ: Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 2000, 36(15):1974-1983.
• [54]Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP: Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics 2009, 2:34. BioMed Central Full Text
• [55]Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC: Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Cancer Res 1988, 48(20):5713-5716.
• [56]Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA: Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006, 116(7):1955-1962.
• [57]Ma J, Chen CS, Blute T, Waxman DJ: Antiangiogenesis enhances intratumoral drug retention. Cancer Res 2011, 71(7):2675-2685.
• [58]Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99(19):1441-1454.
• [59]Kern W, Braess J, Friedrichsen S, Kaufmann CC, Schleyer E, Hiddemann W: Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. J Cancer Res Clin Oncol 2001, 127(1):64-68.
• [60]Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S: Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003, 9(16 Pt 1):5896-5901.
• [61]Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV: Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005, 55(3):277-285.
• [62]Lamendola DE, Duan Z, Yusuf RZ, Seiden MV: Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 2003, 63(9):2200-2205.
• [63]Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M: In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997, 75(6):869-877.
• [64]Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano T, Tomoda Y: Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro. Cancer Chemother Pharmacol 1990, 26(5):333-339.
• [65]Gore ME, Preston N, A'Hern RP, Hill C, Mitchell P, Chang J, Nicolson M: Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer 1995, 71(6):1308-1310.
• [66]Oparka R, McCluggage WG, Herrington CS: Peritoneal mesothelial hyperplasia associated with gynaecological disease: a potential diagnostic pitfall that is commonly associated with endometriosis. J Clin Pathol 2011, 64(4):313-318.
• [67]Pineiro R, Maffucci T, Falasca M: The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 2010, 30(2):142-152.
• [68]Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, DeLoia JA: Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging. Nucl Med Biol 2011, 38(4):485-491.
• [69]Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K, Yamamoto M: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009, 15(10):3423-3432.
• [70]Sterpetti P, Marucci L, Candelaresi C, Toksoz D, Alpini G, Ugili L, Baroni GS, Macarri G, Benedetti A: Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals. Am J Physiol Gastrointest Liver Physiol 2006, 290(4):G624-G632.
• [71]Kaaijk P, Kaspers GJ, Van Wering ER, Broekema GJ, Loonen AH, Hahlen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJ: Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Br J Cancer 2003, 88(5):775-781.
• [72]Shain KH, Dalton WS: Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 2001, 1(1):69-78.
• [73]Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T: An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 2002, 62(4):1139-1147.
• [74]Deng HB, Parekh HK, Chow KC, Simpkins H: Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. J Biol Chem 2002, 277(17):15035-15043.
• [75]Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011, 12(9):852-861.
• [76]Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB: Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res 2010, 17(4):783-791.
• [77]Banerjee S, Kaye SB, Ashworth A: Making the best of PARP inhibitors in ovarian cancer. Nat Rev Clin Oncol 2010, 7(9):508-519.
• [78]Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D: c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 2011, 4(166):ra19.
• [79]Yamashita T, Miyamoto S, O'Malley B, Li D: The Role of PARP 1 for Cisplatin-Based Chemoresistance. Otolaryngol Head Neck Surg 2010, 143(2S2):P54.
• [80]Cheng JC, Auersperg N, Leung PC: Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Oncogene 2011, 30(9):1020-1031.
• [81]Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, Beaudin J, Piche A, Rancourt C: Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer 2011, 104(6):989-999.
• [82]Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A: Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One 2011, 6(1):e16186.
• [83]Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piche A, Rancourt C: MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Gynecol Oncol 2011, 121(3):434-443.
• [84]Green SK, Francia G, Isidoro C, Kerbel RS: Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther 2004, 3(2):149-159.
• [85]Di Benedetto A, Watkins M, Grimston S, Salazar V, Donsante C, Mbalaviele G, Radice GL, Civitelli R: N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms. J Cell Sci 2010, 123(Pt 15):2640-2648.
• [86]Ke X-S, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Oyan AM, Kalland K-H: Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. PLoS One 2008, 3(10):e3368.
• [87]Braungart E, Hartman E, Bechler K, Hofler H, Atkinson MJ: The intracellular domain of cadherin-11 is not required for the induction of cell aggregation, adhesion or gap-junction formation. Cell Commun Adhes 2001, 8(1):15-27.
• [88]Kiener HP, Brenner MB: Building the synovium: cadherin-11 mediates fibroblast-like synoviocyte cell-to-cell adhesion. Arthritis Res Ther 2005, 7(2):49-54. BioMed Central Full Text
• [89]Shimoyama Y, Tsujimoto G, Kitajima M, Natori M: Identification of three human type-II classic cadherins and frequent heterophilic interactions between different subclasses of type-II classic cadherins. Biochem J 2000, 349(Pt 1):159-167.
• [90]Yoshida K: Fibroblast cell shape and adhesion in vitro is altered by overexpression of the 7a and 7b isoforms of protocadherin 7, but not the 7c isoform. Cell Mol Biol Lett 2003, 8(3):735-741.
• [91]Chu G: Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994, 269(2):787-790.
• [92]Tew KD: Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54(16):4313-4320.
• [93]Gabellini N, Masola V, Quartesan S, Oselladore B, Nobile C, Michelucci R, Curtarello M, Parolin C, Palu G: Increased expression of LGI1 gene triggers growth inhibition and apoptosis of neuroblastoma cells. J Cell Physiol 2006, 207(3):711-721.
• [94]Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK: LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. J Biol Chem 2004, 279(22):23151-23157.
• [95]Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999, 36(2):99-114.
• [96]Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A: Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004, 75(5):448-454.
• [97]Martinez VG, O'Connor R, Liang Y, Clynes M: CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Br J Cancer 2008, 98(3):564-570.
• [98]Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A: Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Mol Cancer Ther 2008, 7(1):19-26.
• [99]Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, Uhlen M, Nilsson P: Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics 2009, 10:365. BioMed Central Full Text
• [100]Jonsdottir K, Storkson R, Krog A, Bukholm IRK: Correlation between mRNA detected by microarrays and qRT-PCR and protein detected by immunohistochemistry of cyclins in tumour tissue from colonic adenocarcinomas. The Open Pathol J 2008, 2:96-101.
• [101]Shebl FM, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A: Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol Biomarkers Prev 2010, 19(4):978-981.